Background. Antibiotic overuse and misuse, the main causes of antibiotic resistance, often result from lack of diagnostic clarity. Delayed pathogen identification paired with nonspecific clinical findings may leave clinicians with insufficient evidence to make definitive decisions regarding the need for antibiotics. The dual stimulus of bacterial toxins and inflammation make Procalcitonin (PCT) unique in its ability to differentiate bacterial infection from other causes of inflammation and thus useful for antibiotic management. The objective of our study was to evaluate the impact of a PCTguided algorithm (PCT-A) on current practice.
Methods. A single-center, retrospective cohort study was conducted to evaluate the impact of adding PCT-A to current stewardship practices. Patient data from four years prior to and four years after PCT-A implementation was compared in critical and acute care patients of all ages receiving parenteral antibiotics for a DRG coded for infection. A baseline PCT was obtained at the time of admission in all patients with suspected or proven bacterial infection. Serial PCT measurements were repeated at 24 hour intervals to evaluate effectiveness of therapy. Outcomes of interest were antibiotic exposure, mortality, 30-day readmission, C. difficile infection (CDI) and adverse drug events (ADE).
Results. 985 patients in the pre PCT-A group were compared with 1167 patients in the post PCT-A group. Antimicrobial stewardship alone in the pre PCT-A group resulted in a median Days of Therapy (DOT) of 17.0 (IQR 8.5-22.5) vs. 9.0 (IQR 6.5-12.0) in the post PCT-A group (between-group difference -8.0 DOT, P < 0.0001). Mortality, readmission, CDI and ADEs were also significantly reduced (-51%, -37%,-60%, -41% respectively) in the post PCT-A group.
Conclusion. The addition of PCT to clinical judgment and antibiotic management practices in a facility with an established stewardship program resulted in a significant reduction in antibiotic exposure and adverse outcome. PCT may improve antibiotic management in situations where diagnostic clarity and resolution of infection are lacking. Methods. In 2015, ASP rounding structure was expanded to include retrospective review of all inpatient antibiotics. Additionally, the clinical pharmacist reviewed restricted antimicrobials and all vancomycin orders daily. For patients requiring interventions, the pharmacist communicated recommendations with the treating physicians. Primary objectives of the ASP team were reduction of inappropriate use of antibiotics and optimization of pharmacy vancomycin dosing guidelines. Clinical and economic data was compared with the 2014 baseline; the outcomes were reviewed for a 2-year period. During this time, the hospital infection control committee also launched a hand-washing campaign.
Disclosures
Results. Direct antimicrobial purchasing costs decreased from 2014 baseline of $852,835 per year to $754,335 in 2015 and $569,042 in 2016. An associated decrease in overall antibiotic utilization was observed, as measured by days of therapy per 1,000 patient-days. Baseline and current drug acquisition costs were reviewed; except for the reduction in linezolid cost, the purchasing cost change does not account for all cost savings realized by the ASP.
During the 2-year period, the percentage of Staphylococcus aureus resistant to methicillin decreased from 42% to 38%. Additionally, improved antibiotic susceptibility or gram-negative organisms were noted. Specifically for Pseudomonas aeruginosa, susceptibility for aztreonam, cefepime, ciprofloxacin, and levofloxacin improved by an average of 20%. For Escherichia coli, quinolone susceptibility improved by an average of 7%.
Conclusion. Expansion of ASP monitoring at a community hospital demonstrated favorable clinical and economic outcomes. The investment in personnel resources required to maintain ASP is offset by the clinical and economic benefit ASP provides. How long these beneficial effects are sustained remains to be determined.
